Display options
Cite
Drye LT, Zandi PP. Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). Dement Geriatr Cogn Dis Extra. 2012;2(1):304-11doi: 10.1159/000341783.
Drye, L. T., & Zandi, P. P. (2012). Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). Dementia and geriatric cognitive disorders extra, 2(1), 304-11. https://doi.org/10.1159/000341783
Drye, Lea T, and Zandi, Peter P. "Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)." Dementia and geriatric cognitive disorders extra vol. 2,1 (2012): 304-11. doi: https://doi.org/10.1159/000341783
Drye LT, Zandi PP. Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):304-11. doi: 10.1159/000341783. Epub 2012 Aug 16. PMID: 22962554; PMCID: PMC3435528.
Copy Download .nbib Format: NLM
Share it on

Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):304-11. doi: 10.1159/000341783. Epub 2012 Aug 16.

Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).

Dementia and geriatric cognitive disorders extra

Lea T Drye, Peter P Zandi

Affiliations

  1. Departments of Epidemiology and Mental Health, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Md., USA.

PMID: 22962554 PMCID: PMC3435528 DOI: 10.1159/000341783

Abstract

BACKGROUND: The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) tested whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent Alzheimer's disease (AD). The results were null. We analyzed ADAPT data to examine if the effects of NSAIDs on AD risk differed depending upon APOE genotype or age as has been suggested by previous observational studies.

METHODS: ADAPT randomized 2,528 cognitively intact older adults to either celecoxib, naproxen sodium or placebo; 2,388 participants provided blood samples for APOE genotyping. Proportional hazards regression was used to estimate the effects of naproxen or celecoxib versus placebo on incident AD by age at enrollment and APOE genotype.

RESULTS: The proportion of subjects providing a biological sample did not differ between the treatment groups. In models of AD risk, none of the tests for 2-way interactions between either NSAID and age or APOE genotype were significant (p > 0.05).

CONCLUSIONS: The data did not support the hypothesis that the association between NSAIDs and AD risk differed by age or APOE genotype.

Keywords: Age; Alzheimer's disease; Apolipoprotein E; Clinical trial; Prevention

References

  1. Neuroepidemiology. 2004 May-Jun;23(3):135-43 - PubMed
  2. Neurology. 2008 Jan 1;70(1):17-24 - PubMed
  3. PLoS Clin Trials. 2006 Nov 17;1(7):e33 - PubMed
  4. BMC Geriatr. 2005 Jan 12;5:2 - PubMed
  5. N Engl J Med. 2001 Nov 22;345(21):1515-21 - PubMed
  6. CNS Neurol Disord Drug Targets. 2010 Apr;9(2):132-9 - PubMed
  7. Neurology. 1984 Jul;34(7):939-44 - PubMed
  8. Neurology. 2002 Sep 24;59(6):880-6 - PubMed
  9. Arch Neurol. 2008 Jul;65(7):896-905 - PubMed
  10. Control Clin Trials. 2002 Feb;23(1):93-9 - PubMed
  11. Neurology. 2007 May 22;68(21):1800-8 - PubMed
  12. Alzheimers Dement. 2009 Mar;5(2):93-104 - PubMed

Publication Types